Starpharma Pty Ltd Patent applications |
Patent application number | Title | Published |
20140171375 | MACROMOLECULES - The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described. | 06-19-2014 |
20130116432 | MODIFIED MACROMOLECULE - The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups. | 05-09-2013 |
20110230348 | PEHAM Dendrimers for Use in Agriculture - Specific PEHAM dendrimers are used in a formulation with an active agent for agricultural purposes, particularly for increasing the efficacy of the active agent in various ways, such as by improving solubility of the active agent in the formulation, by improving adhesion and penetration of the active agent to plant surfaces, by improving the water-fastness of the active agent to the plant or seed, by increasing soil penetration of the active agent to reach the plant roots or under soil parts, or by reducing soil adhesion of the active agent to reach the plant roots or under soil parts, or reducing enzymatic degradation of the active agent by the plant or seed or microorganisms in the soil. | 09-22-2011 |
20100324146 | Dendrimeric Enzyme Inhibitors - The present invention relates generally to the use of dendrimer compounds bearing anionic surface groups as inhibitors of hyaluronidase and their use in the treatment of diseases and conditions in which excessive, abnormal or unwanted levels of hyaluronidase are involved or implicated, or in the treatment of diseases or conditions in which the presence or administration of hyaluronic acid is therapeutically effective. The present invention also relates to pharmaceutical compositions and methods for the treatment of such diseases and conditions. | 12-23-2010 |
20100292148 | TARGETED POLYLYSINE DENDRIMER THERAPEUTIC AGENT - The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them. | 11-18-2010 |
20100278750 | POLYLYSINE DENDRIMER CONTRAST AGENT - The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent. | 11-04-2010 |
20090324535 | MODIFIED MACROMOLECULE - The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups. | 12-31-2009 |